We are live on ! Find out more
TEVA icon

Teva Pharmaceuticals
TEVA

429 hedge funds and large institutions have $5.14B invested in Teva Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 35 funds opening new positions, 124 increasing their positions, 142 reducing their positions, and 40 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 5 → 5 (0)

6% less call options, than puts

Call options by funds: $296M | Put options by funds: $315M

3% less funds holding

Funds holding: 440 → 429 (-11)

2.99% less ownership

Funds ownership: 50.84% → 47.85% (-3%)

7% less capital invested

Capital invested by funds: $5.55B → $5.14B (-$411M)

13% less first-time investments, than exits

New positions opened: 35 | Existing positions closed: 40

13% less repeat investments, than reductions

Existing positions increased: 124 | Existing positions reduced: 142

Holders
429
Holders Change
-11
Holders Change %
-2.5%
% of All Funds
7.51%
Holding in Top 10
5
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.09%
New
35
Increased
124
Reduced
142
Closed
40
Calls
$296M
Puts
$315M
Net Calls
-$18.9M
Net Calls Change
+$23.5M

Top Buyers

Rank Fund Capital Flow
1
MMH
Menora Mivtachim Holdings
Israel
+$30.1M
2
BMO
Beck Mack & Oliver
New York
+$27.3M
3
PF
Phoenix Financial
Israel
+$24.5M
4
Jane Street
Jane Street
New York
+$24.4M
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$24.3M

Top Sellers

Rank Fund Capital Flow
1
Capital World Investors
Capital World Investors
California
-$404M
2
Capital Research Global Investors
Capital Research Global Investors
California
-$35.4M
3
Norges Bank
Norges Bank
Norway
-$21.9M
4
Citigroup
Citigroup
New York
-$17.5M
5
JP Morgan Chase
JP Morgan Chase
New York
-$12M
Name Holding Trade Value Shares
Change 		Change in
Stake
Dimensional Fund Advisors
26
Dimensional Fund Advisors
Texas
$34.4M +$2.56M +272,981 +8%
Goldman Sachs
27
Goldman Sachs
New York
$31.8M -$6.35M -678,213 -17%
Citadel Advisors
28
Citadel Advisors
Florida
$28.7M -$837K -89,390 -3%
Bank of America
29
Bank of America
North Carolina
$28.3M +$7.64M +816,035 +39%
Deutsche Bank
30
Deutsche Bank
Germany
$28.3M +$8.44M +901,421 +45%
Bank of Montreal
31
Bank of Montreal
Ontario, Canada
$27.7M -$6.44M -687,510 -20%
Grantham, Mayo, Van Otterloo & Co (GMO)
32
Grantham, Mayo, Van Otterloo & Co (GMO)
Massachusetts
$27.3M +$2.37M +252,800 +10%
Sumitomo Mitsui Trust Group
33
Sumitomo Mitsui Trust Group
Japan
$26.6M -$608K -64,943 -2%
D.E. Shaw & Co
34
D.E. Shaw & Co
New York
$26.3M +$24.3M +2,595,704 +2,521%
Morgan Stanley
35
Morgan Stanley
New York
$25.8M +$2.62M +279,384 +12%
FLAM
36
First Light Asset Management
Minnesota
$25.5M -$3.28M -350,061 -12%
A
37
AustralianSuper
Australia
$23.7M -$3.97M -424,038 -15%
Group One Trading
38
Group One Trading
Illinois
$21.8M +$2.45M +261,998 +13%
PMG
39
Private Management Group
California
$21.3M +$757K +80,842 +4%
Citigroup
40
Citigroup
New York
$20.3M -$17.5M -1,866,840 -47%
American Century Companies
41
American Century Companies
Missouri
$20.2M -$829K -88,519 -4%
UBS AM
42
UBS AM
Illinois
$18.6M +$1.23M +130,872 +7%
Bank of New York Mellon
43
Bank of New York Mellon
New York
$17.5M +$305K +32,617 +2%
Millennium Management
44
Millennium Management
New York
$16.6M +$14.4M +1,534,493 +912%
IAM
45
Ion Asset Management
Israel
$15.9M +$15.3M +1,635,446 New
PI
46
PGGM Investments
Netherlands
$15.7M – – –
VanEck Associates
47
VanEck Associates
New York
$15.7M +$3.65M +390,180 +32%
UBS Group
48
UBS Group
Switzerland
$15.5M +$2.48M +265,204 +20%
BM
49
Bridger Management
New York
$14.6M – – –
BNP Paribas Financial Markets
50
BNP Paribas Financial Markets
France
$14.6M -$5.47M -584,008 -28%
1
2
3 4 5

TEVA Hedge Fund Activity: Q3 2021 in Review

429 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Teva Pharmaceuticals (TEVA) for Q3 2021, worth a combined $5.14B — down 7.4% from $5.55B a quarter earlier.

Sellers outnumbered buyers: 40 funds closed out of TEVA and 35 opened new positions — a net loss of 5 holders — while 142 trimmed existing stakes and 124 added.

The largest buyer was Menora Mivtachim Holdings, adding an estimated $30.1M. The largest seller was Capital World Investors, cutting an estimated $404M.

  • 429 institutional investors held Teva Pharmaceuticals (TEVA) as of Q3 2021, down from 440 in Q2 2021.
  • Funds reported $5.14B of Teva Pharmaceuticals stock for Q3 2021, down 7.4% quarter-over-quarter.
  • 35 funds opened new Teva Pharmaceuticals positions in Q3 2021 and 40 closed out, a net change of -5 holders.
  • The largest Teva Pharmaceuticals buyer in Q3 2021 was Menora Mivtachim Holdings, an estimated $30.1M added.
  • The largest Teva Pharmaceuticals seller in Q3 2021 was Capital World Investors, an estimated $404M sold.

Based on aggregated 13F filings for Q3 2021.